[AACR] Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy |
|
This post will be closed automatically in 2026-09-17 18:01
Best Answer
Yesterday 17:25
|
| |
30
Preoperative Chemoimmunotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab for Previously Irradiated Recurrent HNSCC: A Prospective Phase II Trial
30
Two Costimulations Are Better Than One: Role of Endogenous CD28 in 4-1BB CAR T Cells
30
Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
30
Abstract 2455: AI-based robust testicular cancer triaging, a promise for an efficient and cost-effective diagnostic/predictive modality
100
Perivascular Niche–Resident Alveolar Macrophages Promote Interstitial Pneumonitis Related to Trastuzumab Deruxtecan Treatment
